Selenocarbamates As a Prodrug-Based Approach to Carbonic Anhydrase Inhibition

ChemMedChem. 2022 Jun 3;17(11):e202200085. doi: 10.1002/cmdc.202200085. Epub 2022 Mar 23.

Abstract

A study on the activity of selenocarbamates as a novel chemotype acting as carbonic anhydrase (CA, EC 4.2.1.1) inhibitors is reported. Undergoing CA-mediated hydrolysis, selenocarbamates release selenolates behaving as zinc binding groups and effectively inhibiting CAs. A series of selenocarbamates characterised by high molecular diversity and complexity have been studied against different human CA isoforms such as hCA I, II, IX and XII. Selenocarbamates behave as masked selenols with potential biological applications as prodrugs for CAs inhibition-based strategies. X-ray studies provided insights into the binding mode of this novel class of CA inhibitors.

Keywords: X-ray crystallography; carbonic anhydrase inhibitors; inhibition mechanism; selenium; selenocarbamates.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, Neoplasm / metabolism
  • Carbonic Anhydrase II
  • Carbonic Anhydrase IX / metabolism
  • Carbonic Anhydrase Inhibitors / chemistry
  • Carbonic Anhydrases* / metabolism
  • Humans
  • Molecular Structure
  • Prodrugs* / pharmacology
  • Structure-Activity Relationship

Substances

  • Antigens, Neoplasm
  • Carbonic Anhydrase Inhibitors
  • Prodrugs
  • Carbonic Anhydrase II
  • Carbonic Anhydrase IX
  • Carbonic Anhydrases